1. Pink Sheet

Metered Dose Inhaler Propellant Transition: US FDA Eager To Avoid Replay Of CFC-To-HFA ‘Complexity’

 
• By Michael McCaughan

The US FDA wants a smoother transition to newer “low global warming potential” propellants in metered dose inhalers than the prior transition away from CFCs.

The FDA wants the transition to "low global warming potential" metered dose inhaler propellants to have a minimal impact on patients. (Shutterstock)
Key Takeaways
  • The FDA hopes the transition away from HFA propellants in metered dose inhalers is not as complicated as the transition from CFC to HFA propellants.
  • Sponsors are not expected to reformulate their products, but supply chain and cost problems are expected.
  • During a recent workshop, the FDA outlined a development framework that eventually could become a guidance document.

The US Food and Drug Administration is planning to transition away from the hydrofluoroalkane (HFA) propellants currently used in metered dose inhalers and is eager to avoid many of the...

“The CFC to HFA transition was a very complex, multi-year process … that was very complicated and burdensome for us, and as well as for industry,” Sally Seymour, director of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Pathways & Standards

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

EMA Says Digital Transformation A ‘Fundamental Shift’ In Meeting Regulatory Challenges

 
• By Eliza Slawther

Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.